ClinicalTrials.Veeva

Menu

Efficacy and Safety of Vaginal Radiofrequency for Vulvovaginal Atrophy in Breast Cancer Patients (RF-Vaginale)

C

Centre Oscar Lambret

Status

Enrolling

Conditions

Breast Cancer
Vaginal Dryness
Vulvovaginal Atrophy

Treatments

Other: Local hydratation
Device: GynWave-360

Study type

Interventional

Funder types

Other

Identifiers

NCT06900374
2024-A01126-41 (Other Identifier)
RF-Vaginale-2401

Details and patient eligibility

About

This Phase III, randomized, balanced, parallel-group, multicenter trial aims to evaluate the effect of vaginal radiofrequency on symptoms of vaginal dryness at six months. The study compares vaginal radiofrequency treatment with non-hormonal hydration therapy in a population of patients undergoing adjuvant hormonal therapy with aromatase inhibitors, with or without LHRH agonists, for breast cancer.

Patients will be randomly assigned to one of two parallel treatment groups until the six-month assessment:

The first group will receive the reference treatment, which consists of local hydration using a hyaluronic acid-based treatment applied three times a week. Additionally, investigators may incorporate supportive measures at their discretion, such as physiotherapy or vaginal dilators.

The second group will receive the same reference treatment combined with vaginal radiofrequency therapy. This intervention consists of three sessions, each spaced 4 to 6 weeks apart.

Full description

This study aims to see if vaginal radiofrequency therapy can help reduce vaginal dryness in women receiving hormone therapy for breast cancer.

The participants are divided into two groups:

One group will use a non-hormonal vaginal moisturizer (hyaluronic acid) three times a week. If needed, they can also use other supportive treatments like physiotherapy or vaginal dilators.

The other group will receive the same moisturizer treatment but will also have three sessions of vaginal radiofrequency therapy, with each session spaced 4 to 6 weeks apart.

After six months, researchers will compare the two groups to see if vaginal radiofrequency provides additional benefits in relieving vaginal dryness.

Enrollment

75 estimated patients

Sex

Female

Ages

40+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

INCLUSION CRITERIA :

  • Patient over 40 years
  • Presenting disabling vaginal dryness symptoms despite well-administered local moisturizing treatment, attested by a vaginal dryness score ≥3
  • Patient undergoing adjuvant treatment for breast cancer
  • Patient treated with aromatase inhibitors +/- LHRH agonist for at least 3 months with a planned remaining duration of at least 12 months
  • Patient affiliated to a social security organization
  • Patient having signed the informed consent for the present study

EXCLUSION CRITERIA:

  • Contraindications related to the radiofrequency technique:

    • Ongoing urinary tract infection
    • Pacemaker
    • IUD intrauterine device
    • Pregnancy
  • Mucocutaneous disease with vulvovaginal localization: infection, sore, scleratrophic lichen, psoriasis, eczema, etc.

  • Neurodegenerative disease with perineal involvement

  • Current or recent treatment (within the last 12 months) with other physical methods: vaginal laser, photobiomodulation, PRP injection, hyaluronic acid injection or lipo-modeling.

  • Pregnant or breast-feeding women

  • Patients under guardianship or trusteeship.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

75 participants in 2 patient groups

Vaginal radiofrequency treatment
Experimental group
Description:
The evaluator will be blinded to the intervention (different investigator for vaginal radiofrequency sessions and clinical evaluation consultationsup to 6 months, M0, M3 and M6). The blinding will be lifted after the 6-month evaluation, with the possibility of radiofrequency treatment for patients in the control group who are not sufficiently relieved.
Treatment:
Device: GynWave-360
Other: Local hydratation
Reference treatment
Active Comparator group
Description:
Local hydration: hyaluronic acid-based treatment, 3 applications per week Possibility of resorting to associated measures chosen by the investigator (physical therapy, vaginal dilators, etc.), excluding physical treatments (vaginal laser, photobiomodulation, PRP injection, hyaluronic acid injection, or lipomodelling).
Treatment:
Other: Local hydratation

Trial contacts and locations

1

Loading...

Central trial contact

Fanny BEN OUNE

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems